Health Care [ 4/12 ] | Life Sciences Tools & Services [ 21/72 ]
NYSE | Common Stock
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.
The company operates through Life Science and Clinical Diagnostics segments.
The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety.
This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories.
The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market.
This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market.
It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories.
In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers.
Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 1, 24 | 3.11 Increased by +3.67% | 2.02 Increased by +53.96% |
| May 7, 24 | 2.29 Decreased by -31.44% | 2.15 Increased by +6.51% |
| Feb 15, 24 | 3.10 Decreased by -6.34% | 2.82 Increased by +9.93% |
| Oct 26, 23 | 2.33 Decreased by -10.38% | 2.78 Decreased by -16.19% |
| Aug 3, 23 | 3.00 Decreased by -11.24% | 2.68 Increased by +11.94% |
| May 4, 23 | 3.34 Decreased by -32.39% | 3.54 Decreased by -5.65% |
| Feb 16, 23 | 3.31 Increased by +3.12% | 3.45 Decreased by -4.06% |
| Oct 27, 22 | 2.60 Decreased by -29.92% | 2.78 Decreased by -6.47% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 632.12 M Decreased by -7.15% | 106.26 M Increased by +164.70% | Increased by +16.81% Increased by +169.68% |
| Jun 30, 23 | 681.11 M Decreased by -1.45% | -1.16 B Decreased by -25.35% | Decreased by -170.64% Decreased by -27.19% |
| Mar 31, 23 | 676.84 M Decreased by -3.32% | 68.96 M Increased by +102.05% | Increased by +10.19% Increased by +102.12% |
| Dec 31, 22 | 730.29 M Decreased by -0.34% | 827.73 M Increased by +152.60% | Increased by +113.34% Increased by +152.78% |
| Sep 30, 22 | 680.80 M Decreased by -8.87% | -164.23 M Decreased by -104.18% | Decreased by -24.12% Decreased by -104.59% |
| Jun 30, 22 | 691.10 M Decreased by -3.47% | -927.18 M Decreased by -201.43% | Decreased by -134.16% Decreased by -205.07% |
| Mar 31, 22 | 700.06 M Decreased by -3.68% | -3.37 B Decreased by -444.75% | Decreased by -481.33% Decreased by -457.91% |
| Dec 31, 21 | 732.77 M Decreased by -7.23% | -1.57 B Decreased by -287.54% | Decreased by -214.76% Decreased by -302.15% |